Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation.

Gallamini A, Fiore F, Sorasio R, Meignan M.

Leuk Lymphoma. 2009 Nov;50(11):1761-4. doi: 10.3109/10428190903308072.

PMID:
19883305
2.

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.

Evens AM, Kostakoglu L.

Blood. 2014 Nov 27;124(23):3356-64. doi: 10.1182/blood-2014-05-577627. Review. Erratum in: Blood. 2015 Apr 9;125(15):2450.

3.

Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?

Gallamini A, Kostakoglu L.

Blood. 2012 Dec 13;120(25):4913-20. doi: 10.1182/blood-2012-03-403790. Epub 2012 Aug 28.

4.

Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma.

Adams HJ, Kwee TC.

Eur J Haematol. 2016 Dec;97(6):491-498. doi: 10.1111/ejh.12791. Epub 2016 Sep 14. Review.

PMID:
27528557
5.

Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose for initial staging of hodgkin lymphoma: a single center experience in Brazil.

Cerci JJ, Pracchia LF, Soares Junior J, Linardi Cda C, Meneghetti JC, Buccheri V.

Clinics (Sao Paulo). 2009;64(6):491-8.

6.

Early interim PET scan in Hodgkin lymphoma: where do we stand?

Gallamini A, Hutchings M, Avigdor A, Polliack A.

Leuk Lymphoma. 2008 Apr;49(4):659-62. doi: 10.1080/10428190801888704. Review.

PMID:
18398732
7.

FDG-PET imaging for Hodgkin lymphoma: current use and future applications.

Kostakoglu L, Evens AM.

Clin Adv Hematol Oncol. 2014 Jan;12(1):20-35. Review.

PMID:
25000313
8.

Role of PET in lymphoma.

Gallamini A, Borra A.

Curr Treat Options Oncol. 2014 Jun;15(2):248-61. doi: 10.1007/s11864-014-0278-4. Review.

PMID:
24619427
9.

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A.

J Clin Oncol. 2007 Aug 20;25(24):3746-52. Epub 2007 Jul 23.

PMID:
17646666
11.

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.

Evens AM, Kostakoglu L.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):135-43. doi: 10.1182/asheducation-2014.1.135. Epub 2014 Nov 18. Review. Erratum in: Hematology Am Soc Hematol Educ Program. 2015;2015:652.

PMID:
25696846
12.

Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift?

Kostakoglu L, Gallamini A.

J Nucl Med. 2013 Jul;54(7):1082-93. doi: 10.2967/jnumed.113.120451.

13.

Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma.

Kobe C, Dietlein M, Fuchs M.

Leuk Lymphoma. 2010 Mar;51(3):552-3. doi: 10.3109/10428190903585468. No abstract available.

PMID:
20141443
14.

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.

Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, Meignan M, Mikhaeel GN, Loft A, Zaucha JM, Seymour JF, Hofman MS, Rigacci L, Pulsoni A, Coleman M, Dann EJ, Trentin L, Casasnovas O, Rusconi C, Brice P, Bolis S, Viviani S, Salvi F, Luminari S, Hutchings M.

Haematologica. 2014 Jun;99(6):1107-13. doi: 10.3324/haematol.2013.103218. Epub 2014 Mar 21.

15.
16.

FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?

Hutchings M.

Hematol Oncol Clin North Am. 2014 Feb;28(1):87-103. doi: 10.1016/j.hoc.2013.10.008. Review.

PMID:
24287070
17.

Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma.

Hutchings M, Loft A, Hansen M, Berthelsen AK, Specht L.

Eur J Haematol. 2007 Mar;78(3):206-12. Epub 2007 Jan 23.

PMID:
17253974
18.

FDG-PET in the clinical management of Hodgkin lymphoma.

Hutchings M, Eigtved AI, Specht L.

Crit Rev Oncol Hematol. 2004 Oct;52(1):19-32. Review.

PMID:
15363464
19.

Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma.

Tirumani SH, LaCasce AS, Jacene HA.

PET Clin. 2015 Apr;10(2):207-25. doi: 10.1016/j.cpet.2014.12.005. Epub 2015 Jan 24. Review.

PMID:
25829087
20.

Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.

Hutchings M, Loft A, Hansen M, Pedersen LM, Berthelsen AK, Keiding S, D'Amore F, Boesen AM, Roemer L, Specht L.

Haematologica. 2006 Apr;91(4):482-9.

Supplemental Content

Support Center